All Cancer articles – Page 18
-
WebinarImmunotherapy advancements: transforming cancer treatment
In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint ...
-
NewsBreast cancer genetic variants in women of African ancestry
Researchers identified variants in three loci that were associated with risk of triple-negative breast cancer.
-
NewsNanoparticle targets primary tumours and brain metastases
A specialised drug-loaded nanoparticle, which can cross the blood-brain barrier, shrunk both breast tumours and breast cancer cells.
-
NewsAssociations of AML MRD levels with posttransplant clinical outcomes
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
-
NewsNew methodologies to find microbiome biomarkers
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
-
NewsFirst animal model for Kaposi sarcoma developed
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
-
NewsHow tumours prevent formation of immune responses
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
-
NewsMini-colons reveal complex process of tumorigenesis ex vivo
The mini-colons are topobiologically complex, can be induced to develop tumours in targeted areas and reduce the use of animal models.
-
NewsNew single-cell lipidomics method may unlock cancer treatments
A new method for a fragmentation-based identification of lipids could enable the study of cancer cells in detail not seen before.
-
NewsTargeting RAS to overcome FLT3 AML drug resistance
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
-
NewsDrug-loaded 3D printed films could revolutionise liver cancer treatment
The new films killed over 80 percent of cancer cells, reduced recurrence rates and minimised undesirable chemotherapy side effects.
-
NewsExplaining uveal melanoma’s resistance to conventional immunotherapies
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
-
NewsNew screening method for HPV-positive head and neck cancer
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
-
ArticleThe immune system’s role in lung cancer risk
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
-
NewsElucidating the mechanism that initiates cancer cachexia
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
-
NewsMelanoma tumours produce altBRAFs by genomic deletions
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
-
NewsProteogenomic signatures: metastatic prostate cancer risk
Mutation signatures and recurrent copy number alterations correlated with a higher risk for disease progression.
-
NewsLink identified between bacteria and cancer treatment efficacy
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
-
News
B-ALL: combination therapy effectively controls high-risk subtypes
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
-
Article
HIF inhibition: a potential therapeutic approach for cancers
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.